{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:35Z","timestamp":1793814035450,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12149-026-02193-1","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:48:48Z","timestamp":1773820128000},"page":"823-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lesion-level quantitative Lu-177 PSMA SPECT\/CT SUV metrics are associated with interim treatment response in mCRPC: a PET-correlated study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-463X","authenticated-orcid":false,"given":"Berkay","family":"\u00c7a\u011fda\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Kardelen","family":"\u00c7a\u011fda\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alptu\u011f \u00d6zer","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"\u015ean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil\u00fcfer","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2193_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2193_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review: The Epidemiology of CRPC. Int J Clin Pract. 2011;65:1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract"},{"key":"2193_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","volume":"66","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Siech C, Hoeh B, Koll F, Humke C, Tilki D, et al. Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Open Sci. 2024;66:46\u201354. https:\/\/doi.org\/10.1016\/j.euros.2024.06.010.","journal-title":"Eur Urol Open Sci"},{"key":"2193_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0090-4295(97)00177-5","volume":"49","author":"WDW Heston","year":"1997","unstructured":"Heston WDW. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: A novel folate hydrolase. Urology. 1997;49:104\u201312. https:\/\/doi.org\/10.1016\/S0090-4295(97)00177-5.","journal-title":"Urology"},{"key":"2193_CR5","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124I\/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280\u201392. https:\/\/doi.org\/10.1007\/s00259-014-2713-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2193_CR6","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II Study of Lutetium-177\u2013Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2013;19:5182\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0231.","journal-title":"Clin Cancer Res"},{"key":"2193_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. JCO. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"JCO"},{"key":"2193_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","volume":"50","author":"JC Dickson","year":"2023","unstructured":"Dickson JC, Armstrong IS, Gabi\u00f1a PM, Denis-Bacelar AM, Krizsan AK, Gear JM, et al. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2023;50:980\u201395. https:\/\/doi.org\/10.1007\/s00259-022-06028-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2193_CR9","doi-asserted-by":"publisher","first-page":"600690","DOI":"10.3389\/fonc.2020.600690","volume":"10","author":"SKB Spohn","year":"2020","unstructured":"Spohn SKB, Kramer M, Kiefer S, Bronsert P, Sigle A, Schultze-Seemann W, et al. Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference. Front Oncol. 2020;10:600690. https:\/\/doi.org\/10.3389\/fonc.2020.600690.","journal-title":"Front Oncol"},{"key":"2193_CR10","doi-asserted-by":"publisher","first-page":"879089","DOI":"10.3389\/fonc.2022.879089","volume":"12","author":"S Zschaeck","year":"2022","unstructured":"Zschaeck S, Andela SB, Amthauer H, Furth C, Rogasch JM, Beck M, et al. Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients. Front Oncol. 2022;12:879089. https:\/\/doi.org\/10.3389\/fonc.2022.879089.","journal-title":"Front Oncol"},{"key":"2193_CR11","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1038\/s41598-023-35628-0","volume":"13","author":"F Weitzer","year":"2023","unstructured":"Weitzer F, Pernthaler B, Plhak E, Riedl R, Aigner RM. Diagnostic value of two-time point [68Ga]Ga-PSMA-11 PET\/CT in the primary staging of untreated prostate cancer. Sci Rep. 2023;13:8297. https:\/\/doi.org\/10.1038\/s41598-023-35628-0.","journal-title":"Sci Rep"},{"key":"2193_CR12","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50:S122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"2193_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET\/CT Imaging: The PSMA PET Progression Criteria. J Nucl Med. 2020;61:678\u201382. https:\/\/doi.org\/10.2967\/jnumed.119.233817.","journal-title":"J Nucl Med"},{"key":"2193_CR14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA-PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.121.263072. jnumed.121.263072.","journal-title":"J Nucl Med"},{"key":"2193_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/RLU.0000000000003412","volume":"46","author":"P Thuillier","year":"2021","unstructured":"Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges J-P, et al. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT\/CT and 68Ga-DOTATOC PET\/CT in Patients With Neuroendocrine Tumors: A Feasibility Study. Clin Nucl Med. 2021;46:111\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003412.","journal-title":"Clin Nucl Med"},{"key":"2193_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40658-022-00513-8","volume":"9","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Norikane T, Mitamura K, Yamamoto Y, Maeda Y, Fujimoto K, et al. Quantitative [99mTc]Tc-MDP SPECT\/CT correlated with [18F]NaF PET\/CT for bone metastases in patients with prostate cancer. EJNMMI Phys. 2022;9:83. https:\/\/doi.org\/10.1186\/s40658-022-00513-8.","journal-title":"EJNMMI Phys"},{"key":"2193_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"2193_CR18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778\u2013809. https:\/\/doi.org\/10.1007\/s00259-022-05727-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2193_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2967\/jnumed.117.203505","volume":"59","author":"NJ Begum","year":"2018","unstructured":"Begum NJ, Thieme A, Eberhardt N, Tauber R, D\u2019Alessandria C, Beer AJ, et al. The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for177 Lu-Labeled PSMA Peptides. J Nucl Med. 2018;59:929\u201333. https:\/\/doi.org\/10.2967\/jnumed.117.203505.","journal-title":"J Nucl Med"},{"key":"2193_CR20","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.2967\/jnumed.122.264953","volume":"64","author":"M Hohberg","year":"2023","unstructured":"Hohberg M, Reifegerst M, Drzezga A, Wild M, Schmidt M. Prediction of Response to177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET\/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC. J Nucl Med. 2023;64:1758\u201364. https:\/\/doi.org\/10.2967\/jnumed.122.264953.","journal-title":"J Nucl Med"},{"key":"2193_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/diagnostics11030428","volume":"11","author":"F V\u00f6lter","year":"2021","unstructured":"V\u00f6lter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, et al. Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy. Diagnostics. 2021;11:428. https:\/\/doi.org\/10.3390\/diagnostics11030428.","journal-title":"Diagnostics"},{"key":"2193_CR22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2967\/jnumed.122.264770","volume":"64","author":"M Straub","year":"2023","unstructured":"Straub M, Kupferschl\u00e4ger J, Serna Higuita LM, Weissinger M, Dittmann H, La Foug\u00e8re C, et al. Dual-Time-Point Posttherapy177 Lu-PSMA-617 SPECT\/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients\u2019 Outcome. J Nucl Med. 2023;64:1431\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264770.","journal-title":"J Nucl Med"},{"key":"2193_CR23","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/mp.12886","volume":"45","author":"MT Madsen","year":"2018","unstructured":"Madsen MT, Menda Y, O\u2019Dorisio TM, O\u2019Dorisio MS. Technical Note: Single time point dose estimate for exponential clearance. Med Phys. 2018;45:2318\u201324. https:\/\/doi.org\/10.1002\/mp.12886.","journal-title":"Med Phys"},{"key":"2193_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping After Endoradiotherapy with177 Lu-DOTATATE\/DOTATOC by a Single Measurement After 4 Days. J Nucl Med. 2018;59:75\u201381. https:\/\/doi.org\/10.2967\/jnumed.117.193706.","journal-title":"J Nucl Med"},{"key":"2193_CR25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2020","unstructured":"Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation Dosimetry in177 Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT\/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med. 2020;61:1030\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.233411.","journal-title":"J Nucl Med"},{"key":"2193_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12149-019-01376-3","volume":"33","author":"E Acar","year":"2019","unstructured":"Acar E, \u00d6zdo\u011fan \u00d6, Aksu A, Derebek E, Beki\u015f R, \u00c7apa Kaya G. The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. Ann Nucl Med. 2019;33:681\u20138. https:\/\/doi.org\/10.1007\/s12149-019-01376-3.","journal-title":"Ann Nucl Med"},{"key":"2193_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60:517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med"},{"key":"2193_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2967\/jnumed.122.264489","volume":"64","author":"F Kind","year":"2023","unstructured":"Kind F, Eder A-C, Jilg CA, Hartrampf PE, Meyer PT, Ruf J, et al. Prognostic Value of Tumor Volume Assessment on PSMA PET After177 Lu-PSMA Radioligand Therapy Evaluated by PSMA PET\/CT Consensus Statement and RECIP 1.0. J Nucl Med. 2023;64:605\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264489.","journal-title":"J Nucl Med"},{"key":"2193_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11307-024-01900-6","volume":"26","author":"R Eisazadeh","year":"2024","unstructured":"Eisazadeh R, Mirshahvalad SA, Schwieghofer-Zwink G, Hehenwarter L, Rendl G, Gampenrieder S, et al. Pre-treatment 68 Ga-PSMA-11 PET\/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival. Mol Imaging Biol. 2024;26:360\u20139. https:\/\/doi.org\/10.1007\/s11307-024-01900-6.","journal-title":"Mol Imaging Biol"},{"key":"2193_CR30","doi-asserted-by":"publisher","unstructured":"Ozkan E, Demir B, Soydal C, Araz M, Dursun E, Kucuk NO, et al. Prediction of [177Lu]Lu-PSMA-617 treatment response with [68Ga]Ga-PSMA-11 PET-derived variables and correlation of the overall survival with serum PSA and PSMA PET-based response criteria. Revista Espa\u00f1ola de Med Nuclear e Imagen Mol (English Edition). 2025;500208. https:\/\/doi.org\/10.1016\/j.remnie.2025.500208.","DOI":"10.1016\/j.remnie.2025.500208"},{"key":"2193_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull W-E, W\u00e4ngler C, Mier W, et al. 68 Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug Chem. 2012;23:688\u201397. https:\/\/doi.org\/10.1021\/bc200279b.","journal-title":"Bioconjug Chem"},{"key":"2193_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2967\/jnumed.117.202945","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Fendler WP, Eiber M, Gartmann J, Chu F-I, Nickols NG, et al. Impact of68 Ga-PSMA-11 PET\/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018;59:434\u201341. https:\/\/doi.org\/10.2967\/jnumed.117.202945.","journal-title":"J Nucl Med"},{"key":"2193_CR33","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl F-X, Buck AK, Rowe SP, Higuchi T, Seitz AK, et al. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3269\u201376. https:\/\/doi.org\/10.1007\/s00259-022-05744-6.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02193-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02193-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02193-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:10:42Z","timestamp":1781946642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02193-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2193"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02193-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee of Bilkent City Hospital (Approval number: E1-4136, Date: 18.10.2023). Informed consent was waived due to the retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No potential conflicts of interest were disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}